




# SOHO France

## Congrès en hématologie

16 - 18 Novembre 2022

Campus Pierre et Marie Curie  
4, Place Jussieu  
75005 Paris

Auditorium du CICSU - Sciences Sorbonne  
Université  
Patio 44-55 | niveau Jussieu



[www.soho-france.com](http://www.soho-france.com)

en association avec

# COMITÉ SCIENTIFIQUE

## Présidente du Comité Scientifique

Mauricette MICHALLET (Hématologue, Centre Léon Bérard, Lyon)

## Membres du Comité Scientifique

- Amine BELHABRI (Hématologue, Centre Léon Bérard, Lyon)
- Sylvain CHOQUET (Hématologue, Hôpital Pitié-Salpêtrière, Paris)
- Florence CYMBALISTA (Hématologue, Hôpital Avicenne, Bobigny)
- Roch HOUOT (Hématologue, CHU de Rennes)
- Jean-Jacques KILADJIAN (Hématologue, Hôpital Saint-Louis, Paris)
- Xavier LELEU (Hématologue, CHU de Poitiers)
- François-Xavier MAHON (Hématologue, Institut Bergonié, Bordeaux)
- Anne-Sophie MICHALLET (Hématologue, Centre Léon Bérard, Lyon)
- Franck NICOLINI (Hématologue, Centre Léon Bérard, Lyon)
- Sophie PARK (Hématologue, CHU Grenoble Alpes)
- Christian RECHER (Hématologue, Institut Universitaire du Cancer de Toulouse)
- Philippe ROUSSELOT (Hématologue, Centre Hospitalier de Versailles, Le Chesnay)

# PROGRAMME

Wednesday 16, November 2022

1:30 p.m ..... Opening

2:00 - 2:40 p.m ..... Introduction

**Mauricette MICHALLET** (Hematology, Léon Bérard Center, Lyon),  
**Florence CYMBALISTA** (Hematology, Avicenne Hospital, Bobigny),  
**Hagop KANTARJIAN** (Oncology Hematology, MD Anderson Cancer Center, University of Texas, Houston),  
**Thierry FACON** (Hematology, Claude Huriez Hospital, Lille),  
**Jean-Yves BLAY** (Oncology, Léon Bérard Center, Lyon)

2:40 - 3:40 p.m ..... Session 1 : Chronic Myeloid Leukemia

**Chair: Franck NICOLINI (Hematology, Léon Bérard Center, Lyon)**

ASCIMINIB (Allosteric Inhibitor) : a new step of treatment of CML  
Delphine REA (Hematology, Saint-Louis Hospital, Paris)

20 min.

STOP ITK : french experience  
François-Xavier MAHON (Hematology, Bergonié Institute, Bordeaux)

20 min.

Re-emergence of INTERFERON in CML  
Franck NICOLINI (Hematology, Léon Bérard Center, Lyon)

20 min.

3:40 - 4:10 p.m ..... Break

4:10 - 5:35 p.m ..... Session 2 : Chronic Lymphocytic Leukemia

**Chair: Florence CYMBALISTA (Hematology, Avicenne Hospital, Bobigny)**

Is MRD ready for prime time ?  
Rémi LETESTU (Biological Hematology, Avicenne Hospital, Bobigny)

15 min.

Adverse events and resistance to targeted agents  
Anne QUINQUENEL (Hematology, University Hospital of Reims)

15 min.

Debate : Continuous treatment VS Time limited treatment  
Alain DELMER (Hematology, University Hospital of Reims)

25 min.

VS Anne-Sophie MICHALLET (Hematology, Léon Bérard Center, Lyon)

Future of CLL treatment  
Susan O'BRIEN (Hematology, Oncology, Internal Medecin, MD Anderson Cancer Center, Orange, L.A.)

30 min.

5:35 - 6:35 p.m ..... Session 3 : Myeloproliferative Neoplasms

**Chair: Jean-Jacques KILADJIAN (Hematology, Saint-Louis Hospital, Paris)**

Deciphering TP53 mutant cancer evolution with single-cell multi-omics  
Adam MEAD (Hematology, University of Oxford)

20 min.

Update in the treatment of polycythemia vera  
Jean-Jacques KILADJIAN (Hematology, Saint-Louis Hospital, Paris)

15 min.

Discussion: myelofibrosis: strategy after resistance to RUXOLUTINIB  
> Place and timing of allogeneic HCT

25 min.

Marie ROBIN (Hematology, Saint-Louis Hospital, Paris)

&

> Second line therapy in case of ineligibility to allogeneic HCT  
Lydia ROY (Hematology, Henri-Mondor Hospital, Créteil)

6:35 - 6:55 p.m ..... Oral Presentations (selected oral presentations by the scientific committee) 20 min.

# Thursday 17, November 2022

7:30 a.m ..... Opening

8:00 - 9:20 a.m ..... Session 4 : Myelodysplastic Syndromes

**Chairs: Sophie PARK (Hematology, University Hospital of Grenoble Alps)  
Pierre FENEAUX (Hematology, Saint-Louis Hospital, Paris)**

State-of-the-art in low-risk myelodysplasia  
Sophie PARK (Hematology, University Hospital of Grenoble Alps)

20 min.  

State-of-the-art in high-risk myelodysplasia  
Thomas CLUZEAU (Hematology, University Hospital of Nice)

20 min.  

Which therapeutic target in chronic myelomonocytic leukemia?  
Eric SOLARY (Hematology, Gustave Roussy Center, Villejuif)

20 min.  

Current advances in myelodysplastic syndromes with  
SF3B1 mutations

Michaela FONTENAY (Biological Hematology, Cochin Hospital,  
Paris)



9:20 - 9:50 a.m ..... Break

9:50 - 11:15 a.m ..... Session 5 : Acute Lymphoblastic Leukemia

**Chair: Philippe ROUSSELOT (Hematology, Hospital of Versailles, Le Chesnay)**

Chemofree regimens in Ph+ ALL

20 min. 

Sabina CHIARETTI (Cellular Biotechnology, Hematology, Sapienza  
University, Rome)

How much chemotherapy with TKI in Ph+ ALL?

20 min.  

Philippe ROUSSELOT (Hematology, Hospital of Versailles,  
Le Chesnay)

On going research with antibodies and chemotherapy in Pre-B ALL

25 min. 

Hagop KANTARJIAN (Oncology Hematology, MD Anderson Cancer  
Center, University of Texas, Houston)

Novel therapeutic strategies of relevance of T-ALL

20 min.  

Ludovic LHERMITTE (Biological Hematology, Necker-Enfants  
Malades Hospital, Paris)

11:15 - 11:30 a.m ..... Oral Presentations (selected oral presentations by the scientific committee)

15 min.  

11:30 a.m - 1:00 p.m ..... Immunotherapy in myeloma : where do we stand?

**Chair: Mohamad MOHTY (Hematology, Saint-Antoine Hospital, Paris)**

Salomon MANIER (Hematology, University Hospital of Lille)

Philippe MOREAU (Hematology, University Hospital of Nantes)

Catherine PELLAT-DECEUNYNCK (Hematology, University Hospital of Nantes)

1:00 - 2:00 p.m ..... Lunch Break & Poster Walk

2:00 - 3:20 p.m ..... Session 6 : Acute Myeloid Leukemia

**Chair: Arnaud PIGNEUX (Hematology, University Hospital of Bordeaux)**

New strategies for treatment of AML (except anti-IDH  
and Immunotherapy)

Naval G. DAVER (Hematology, MD Anderson Cancer Center, Houston)

20 min. 

Management of IDH mutated AML

Stéphane DE BOTTON (Hematology, Gustave Roussy Center,  
Villejuif)

20 min.  

	Diagnosis and prognosis prediction: NGS, MRD, Artificial Intelligence <b>Torsten HAFLERLACH</b> (Oncology Hematology, MLL Munich Leukemia Laboratory GmbH, Munich)	20 min.
	Debate : Intensive VS Non intensive chemotherapy in « fit » patients <b>Chair: Christian RECHER (Hematology, University Cancer Institute of Toulouse)</b>	20 min.
	Lionel ADÈS (Hematology, Saint-Louis Hospital, Paris) VS Nigel RUSSELL (Hematology, University of Nottingham)	
3:20 - 4:40 p.m .....	Session 7 : Lymphomas <b>Chair: Sylvain CHOQUET (Hematology, Pitié-Salpêtrière Hospital, Paris)</b>	
	The future of bispecific antibodies in lymphoma Guillaume CARTRON (Hematology Université Hospital of Montpellier)	20 min.
	Circulating tumour DNA and lymphoma Fabrice JARDIN (Hematologie, Henri Becquerel Center, Rouen)	20 min.
	The future of autologous hematopoietic cell transplantation in B lymphomas Catherine THIEBLEMONT (Hematology, Saint-Louis Hospital, Paris)	20 min.
	State-of-the-art of anaplastic large cell lymphomas David SIBON (Hematology, Henri-Mondor Hospital, Paris)	20 min.
4:40 - 5:10 p.m.....	Break	
5:10 - 6:45 p.m.....	Session 8 : Multiple Myeloma <b>Chairs: Xavier LELEU (Hematology, University Hospital of Poitiers)</b> <b>Claudio CERCHIONE (Hematology, Romagnolo Institute for the Study of Tumors «Dino Amadori» - IRST IRCSS - Meldola)</b>	
	NGS and myeloma: role in prognosis and minimal residual disease Jill CORRE (Hematology, University Cancer Institute of Toulouse)	20 min.
	First line in multiple myeloma: what is going to change? Cyrille TOUZEAU (Hematology, University Hospital of Nantes)	20 min.
	Relapse in multiple myeloma: how to prolong survival? Mohamad MOHTY (Hematology, Saint-Antoine Hospital, Paris)	20 min.
	Immunotherapy in multiple myeloma: from now to tomorrow Salomon MANIER (Hematology, University Hospital of Lille)	20 min.
	How I manage smoldering myeloma? Claudio CERCHIONE (Hematology, Romagnolo Institute for the Study of Tumors «Dino Amadori» - IRST IRCSS - Meldola)	15 min.

## Friday 18, November 2022

7:30 a.m .....	Opening	
8:00 - 9:20 a.m.....	Session 9 : CART Cells <b>Chair: Roch HOUOT (Hematology, University Hospital of Rennes)</b>	
	Update of CART Cells activity in lymphoma Roch HOUOT (Hematology, University Hospital of Rennes)	20 min.
	Update of CART Cells activity in acute lymphoblastic leukemia Nicolas BOISSEL (Hematology, Saint-Louis Hospital, Paris)	20 min.

	Update of CART Cells activity in myeloma Philippe MOREAU (Hematology, University Hospital of Nantes)	20 min.  
	Overview and perspectives of CART Cells activities in France and in Europe Christian CHABANNON (Paoli-Calmettes Institute, Marseille)	20 min.  
9:20 - 10:20 a.m.....	High risk AML patient care : a new chapter <b>Chair: Mauricette MICHALLET (Hematology, Léon Bérard Center, Lyon)</b> Jean-Baptiste MICOL (Hematology, Gustave Roussy Center, Villejuif) Marie SEBERT (Hematology, Saint-Louis Hospital, Paris)	60 min.  
 <b>Jazz</b> Pharmaceuticals.		
10:20 - 10:50 a.m.....	Break	
10:50 - 11:20 a.m .....	Discussion <b>Chairs: Roch HOUOT (Hematology, University Hospital of Rennes)</b> <b>Nicolas BOISSEL (Hematology, Saint-Louis Hospital, Paris)</b>	
	Bispecific antibodies and CART Cells: which strategy to choose? when? and for whom? (NHL, myeloma and ALL) Roch HOUOT (Hematology, University Hospital of Rennes), Nicolas BOISSEL (Hematology, Saint-Louis Hospital, Paris), Salomon MANIER (Hematology, University Hospital of Lille), & Philippe ROUSSELOT (Hematology, Hospital of Versailles, Le Chesnay).	30 min.  
11:20 a.m - 12:20 p.m....	Closing Remarks <b>Mauricette MICHALLET</b> (Hematology, Léon Bérard Center, Lyon) <b>Hagop KANTARJIAN</b> (Oncology Hematology, MD Anderson Cancer Center, University of Texas, Houston)	60 min.   

## NOS PARTENAIRES



abbvie

ALEXION  
AstraZeneca Rare Disease

astellas

AstraZeneca

BeiGene

Bristol Myers Squibb™

CHUGAI

GILEAD  
Creating Possible

Incyte

janssen

PHARMACEUTICAL COMPANIES OF  
Johnson & Johnson

NOVARTIS

Pierre Fabre

SANDOZ A Novartis Division

sanofi

SERVIER

# NOTES